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Transfer RNA (tRNA) is traditionally considered to be an adaptor molecule that helps ribosomes to
decode messenger RNA (mRNA) and synthesize protein. Recent studies have demonstrated that
tRNAs also serve as a major source of small non-coding RNAs that possess distinct and varied
functions. These tRNA fragments are heterogeneous in size, nucleotide composition, biogenesis
and function. Here we describe multiple roles that tRNA fragments play in cell physiology and
discuss their relevance to human health and disease.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Cellular RNAs are traditionally divided into three ubiquitous
classes: mRNAs possessing protein-coding function, whose
sequence is decoded to produce proteins, ribosomal (r) RNAs
possessing enzymatic activities required for protein synthesis,
and tRNAs that deliver amino acids to the growing polypeptide
chain serving non-(protein)-coding functions. Both rRNAs, as an
integral part of the ribosome, and tRNAs, as carriers of amino acids,
decode nucleotide information on mRNA into the speciﬁc amino
acid sequence synthesized by the ribosome. The discovery of small
non-coding RNAs (ncRNAs) (20–40 nucleotides long) with diverse
regulatory functions has revolutionized modern biology and
medicine. Among these ncRNAs are siRNAs, miRNAs and piRNAs
with well-deﬁned biological functions that rely on the complemen-
tarity of their sequences to RNA targets (reviewed in [1]).
With the development of high-throughput sequencing technol-
ogies, it became apparent that there are many more classes of
small ncRNAs [2]. These novel ncRNAs are produced from other
cellular RNA species by speciﬁc and regulated RNA processing or
cleavage [3]. The sources of such ‘‘non-canonical’’ ncRNAs are
diverse cellular RNAs including tRNAs.The evolutionarily conserved function of tRNA is to help the
ribosome synthesize proteins by decoding nucleotide triplets
thereby linking nucleotide information on mRNA to amino acid
sequence [4,5]. Beyond this canonical function, tRNA is also impli-
cated in a number of other biological processes including cell sig-
naling, cell survival, apoptosis, metabolism of amino acids and
porphyrines, and stress response programs [5,6]. Despite their
small size (73–95 nucleotides), tRNAs are characterized by their
evolutionarily conserved secondary and tertiary structures, exten-
sive post-transcriptional processing and modiﬁcations (up to 100
nucleoside modiﬁcations have been described), extreme stability
and resistance to nucleases [4,5,7]. Moreover, the human genome
contains more than 500 genes encoding over 40 different tRNAs
[8–10].
Identiﬁcation of novel ncRNAs derived from tRNAs, known as
tRNA-derived RNA fragments, has recently gained signiﬁcant
attention. Some of these fragments are derived from precursor
tRNA molecules, others from mature cytoplasmic tRNAs. Some
fragments are constitutive components of all cells, whereas others
are only produced in cells exposed to adverse conditions. The
identiﬁcation of tRNA fragments found in different organisms,
as well as their biogenesis and possible functions, are described
in several recent reviews [5,11–15]. Here, we will only review
the biogenesis and functions of tRNA fragments found in human
cells and discuss their potential roles in the pathobiology of
human diseases.
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High-throughput RNA sequencing has detected distinct classes
of tRNA fragments in mammalian cells. Their abundance varies
between different cell types and tissues showing generally no cor-
relation with abundance of parent tRNAs. Moreover, some of the
fragments are only produced under speciﬁc conditions such as
developmental stage, proliferative status, stress or viral infection
[11–15]. Although tRNA pieces are heterogeneous in size (10–45
nucleotides), they are not products of random tRNA cleavage or
degradation because their ends are precisely deﬁned by RNA
cleavage sequence determinants.
Biogenesis of tRNA is a complex process. Initially, tRNA is tran-
scribed in the form of a precursor (pre-tRNA) containing 50-leader
and 30-trailer sequences and, in some cases, introns in the
anticodon loop [5,6,16–18]. During tRNA maturation, the 50-trailer
is processed by RNase P, the 30-trailer is removed by RNase Z, and
following 30-trailer removal, the 30-end of all human tRNAs is
modiﬁed by the addition of the universal 30-CCA triplet by the
CCA-adding enzyme (also known as TRNT1) (Fig. 1). Intron-
containing tRNAs (32 in humans, which make up less than 10%
of all nuclear-encoded human tRNAs), are processed by a nuclear
tRNA splicing endonuclease (TSEN) complex that excises the intron
and ligates 50- and 30-tRNA exons to form mature tRNA (Fig. 1A).
TSEN cleavage leaves a 20-30-cyclic phosphate at the 30 end of the
50 exon and a 50-hydroxyl (50-OH) at the 50-end of 30-exon. The liga-
tion of 50- and 30-exons can go through two different machineries,
and it is still a matter of debate which mechanism is more com-
monly used [19–24] (Fig. 1A). In the ﬁrst mechanism, RtcB (also
known as HSPC17, or C22orf28) works as an RNA 20,30-cyclic phos-
phate and 50-OH ligase to directly mediate the ligation of both
exons. RtcB is a catalytic subunit of a multimeric protein complex
consisting at least of ﬁve other proteins: ASW (C2orf49), CGI-99
(C14orf166), FAM98B, the DEAD-box helicase DDX1 and archease
(ARCH, or ZBTB8OS). The roles of these subunits in the context of
RNA ligation remain unclear, although a recent study from Popow
et al. suggests that DDX1 and archease facilitate RtcB-mediated
ligation of tRNA exons [25]. In the second mechanism, CLP1 (the
ﬁrst RNA kinase ever identiﬁed [26]) associates with the TSEN
complex to phosphorylate 30-tRNA exons and facilitate further liga-
tion. Molecular details of CLP1-facilitated ligation of tRNA exons
are unknown. While cells can utilize both pathways, their relativeFig. 1. Processing of precursor and mature forms of tRNA in tRNA fragments. (A) Process
(50-leader and 30-trailer (blue)) that have to be removed by RNase P and RNase Z during
exon fragments. Intron (blue)-containing pre-tRNAs are spliced by the TSEN complex. Usu
can accumulate. 50-exons and 30-exons are naturally present in the nucleus as products o
TRNT1 adds CCA to the 30-ends of tRNA. In some cases, 30-trailers accumulate and are e
Mature tRNA can be cleaved in the anticodon loop by angiogenin (ANG) to produce 50-
tRNA in the D arm of tRNA results in the production of small tRNA fragments, 50-tRFs.
containing CCA at their 30-ends (so called 30CCA tRFs). Both 50-tRFs and 30CCA tRFs maycontribution, importance for tRNA metabolism or functional
redundancy is not known.
Importantly, the processing of pre-tRNA and mature tRNA
results in the production of distinct classes of tRNA-derived ncR-
NAs (Fig. 1A and B). tRNA fragments derived from mature tRNA
can be divided into two major types: tRNA halves (or tRNA-
derived, stress-induced RNAs, known as tiRNAs (see below)) and
smaller tRNA fragments (tRFs) (Fig. 1B). tRNA fragments derived
from pre-tRNA are distinguished by the presence of sequences
derived from 50-leader or 30-trailers (Fig. 1A).
2.1. tRNA halves (tiRNAs)
tRNA halves are produced by speciﬁc cleavage in the anticodon
loop to produce 30–35 nucleotide 50-tRNA halves and 40–50 nucle-
otide 30-tRNA halves. Small quantities of these fragments are found
in human cells under normal growth conditions [3,27,28]. Many of
these are splicing intermediates derived from intron-containing
tRNAs [23,29]. In contrast, tiRNAs are produced by stress-induced
(e.g. oxidative stress, heat shock or UV irradiation) cleavage of
mature cytoplasmic tRNAs by the ribonuclease angiogenin (ANG)
[27,30–33]. Cytoplasmic tRNA halves and tiRNAs are probably
the same molecules and these terms can be used interchangeably.
ANG, a member of RNase A superfamily, is a predominantly
nuclear protein that is also found in complex with RNH1 (also
known as RI, or ANG inhibitor) in the cytoplasm (reviewed in
[34]). In response to stress, ANG translocates into cytoplasm from
the nucleus and dissociates from RNH1. Under these conditions,
ANG cleaves cytoplasmic tRNA into 50- and 30-tiRNAs [33]. While
intuitively such cleavage should cause abrupt translational arrest,
this is not observed because only a minor fraction (<5%) of the
tRNA pool is cleaved [27,31,33]. When cells are treated with
recombinant ANG, global translation is reduced by 10–15%. A sim-
ilar reduction in protein synthesis is observed when isolated
endogenous tiRNAs are transfected into cells suggesting that it is
the tRNA fragments rather then the tRNA cleavage that inhibit
protein synthesis. Surprisingly, transfection of 50-tiRNAs, but not
30-tiRNAs, inhibits translation in cultured cells [30]. Moreover only
50-tiRNAs derived from tRNAAla and tRNACys are responsible for the
inhibition of translation [32]. Mechanistically, active tiRNAs inhibit
translation initiation by interfering with the assembly of the cap
binding complex eIF4F (the complex required for canonicaling of precursor tRNA. Transcribed pre-tRNA contains distinct 50- and 30-extensions
tRNA processing. In some cases, the 50-leader is not removed giving rise to 50-leader
ally, such introns are quickly degraded but in some pathological cases linear introns
f intron-containing tRNA splicing. Upon 30-trailer removal, the CCA-adding enzyme
xported to the cytoplasm as 30-U tRFs. (B) Processing of mature cytoplasmic tRNA.
and 30-tRNA halves (or 50- and 30-tiRNAs, respectively. Dicer-dependent cleavage of
Similarly, cleavage in the T arm by Dicer or ANG results in the production of tRFs
also be processed from 50- and 30-tRNA halves, respectively (dashed arrows).
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tional silencer YB-1 [35–38]. 50-tiRNAsAla/Cys possess a terminal
oligoguanine motif that is required to displace the eIF4F complex
and inhibit translation [32]. Inhibition of translation initiation by
50-tiRNAs also induces the assembly of stress granules (SGs)
[30,32], dynamic cytoplasmic RNA foci that possess adaptive and
pro-survival functions. SGs contain translationally-stalled mRNAs,
associated preinitiation factors, speciﬁc RNA-binding proteins
and signaling molecules [39–42]. SGs are typically formed upon
activation of stress-sensing serine/threonine kinases that phos-
phorylate serine residue 51 of eIF2a [43], a molecule that regulates
the Integrated Stress Response to coordinate cell adaptation and
survival under stress conditions (reviewed in [44–46]). However,
tiRNAs assemble SGs in a phospho-eIF2a-independent manner
[30,32] suggesting the existence of an alternative route of signaling
and SG assembly. It is likely that tiRNA-induced translational
reprogramming is not limited to translation inhibition of speciﬁc
transcripts but also involves a number of cellular events initiated
by the assembly of SGs.
While our data suggest that ANG directly cleaves tRNA within
the anticodon loop, Czech et al. proposed two-step mechanism
for ANG-mediated tRNA cleavage [47]. They showed that, in
response to oxidative stress, ANG ﬁrst cleaves the conserved
CCA-end of all tRNAs to remove associated amino acids, and only
then cleaves in the anticodon loop. Moreover, tRNAs with cleaved
CCA ends can serve as substrates for TRNT1 (CCA-adding enzyme)
allowing repair of CCA ends when stress is relieved. While this is a
very attractive scenario, these data are based on in vitro studies
and await in vivo conﬁrmation. Moreover, because ANG cleaves
substrates to produce 20-30-cyclic phosphate at the 30-end of cleav-
age products (e.g. tRNA without CCA-end), TRNT1 must be able to
add CCA trinucleotide to 20-30-phosphate. While some CCA-adding
enzymes (e.g. from Escherichia coli) also have an additional C-ter-
minal domain with phosphohydrolase activity to resolve cyclic
phosphate and/or remove 30-phosphate from the 30-end (reviewed
in [48]), currently it is not known whether Homo sapiens’s TRNT1
alone or in complex with other enzymes can do that in vivo.
ANG-mediated tRNA cleavage is a highly regulated process.
Genome-wide analysis of tiRNAs demonstrates that patterns of
tRNA cleavage are stress-speciﬁc (e.g., oxidative stress vs hyper-
tonic stress), or dependent on stress intensity [27], and phosphor-
ylation of eIF2a, a main trigger of SGs and major player in the
Integrated Stress Response, regulates levels of selected tiRNAs
[27,33]. Interestingly, higher levels of tRNA cleavage correlate with
higher translation rates (e.g., translation inhibitors down-regulate
both translation and tRNA cleavage) suggesting that ANG has bet-
ter access to tRNA when protein synthesis is active [27]. In agree-
ment with this hypothesis, ANG was found on polysomes (pool of
actively translating ribosomes), and in SGs when translation is
inhibited [49]. Modiﬁcations of tRNA anticodon loops also inﬂu-
ences ANG-mediated cleavage. In Drosophila melanogaster, methyl-
ation of selected tRNAs (ValAAC, GlyGCC, AspGTC) protects these
tRNAs from stress- and ANG-induced tRNA cleavage [50].
It must be noted that precise molecular roles for the majority of
50- and 30-tiRNAs as well as their localization, relative abundance,
and stability are yet to been determined. Our studies identiﬁed a
number of RNA-binding proteins as partners of 50- and 30-tiRNAs,
and some of them are both general to tiRNAs and also speciﬁc to
certain tiRNAs (unpublished data and [32]) suggesting possible
specialized tiRNA functions. Moreover, a recent study showed that
ANG-induced tiRNAs inhibit hyperosmotic apoptosis in stressed
cells [51]. This is achieved by the direct binding of tiRNAs to cyto-
chrome c (Cyt c), which is released from mitochondria during
stress to promote apoptosome formation with subsequent caspase
activation. Cyt c bound to tiRNAs fails to trigger apoptosome
formation and execute cell death. Importantly, RNA sequencingof tiRNAs bound to Cyt c suggests that only a subpopulation of tiR-
NAs (both 50- and 30-, about 20 different species) is highly enriched
in these complexes. This study parallels previously reported anti-
apoptotic effects of full size tRNAs that are also able to bind Cyt c
and inhibit apoptosome formation in vitro [52,53]. However, under
stress conditions Cyt c preferentially binds to tiRNAs and not tRNAs
in vivo [51]. Further studies are necessary to characterize the
composition of Cyt c:tiRNA complexes, sequence/structural deter-
minants of tiRNAs contributing to complex formation and also
speciﬁcity of stresses triggering formation of these complexes.
2.2. Diverse tRNA fragments (tRFs)
tRFs are fragments of tRNA or pre-tRNA that are typically
shorter than tRNA halves (12–30 nucleotides). There are several
subclasses of tRFs, which are often difﬁcult to classify. Here, we
will discuss them in terms of their biogenesis and whether they
are derived from mature tRNA or pre-tRNA. Mature tRNAs have a
50-monophosphate group and 30-CCA charged with cognate amino
acid. All nuclear-encoded tRNAs have four base-paired stems (in 50-
30-direction: D arm, anticodon arm, T arm, and acceptor stem)
bridging the conserved D-loop, tRNA-speciﬁc anticodon loop, vari-
able loop and T-loop (Fig. 1B). Compared to mature tRNAs, pre-
tRNAs lack the CCA tail but include a 50-leader starting with tri-
phosphate, a 30-trailer with an oligouridine stretch and, for
intron-containing tRNA, a variable-sized intron (Fig. 1B).
Mature tRNAs can give rise to 50-tRFs and 30CCA-tRFs that are
produced by cleavage of tRNA in the D-loop and in/near the T-loop,
respectively (Fig. 1B). 50-tRFs are 19–21 nt fragments that are
formed by speciﬁc cleavage after conserved nucleotides G18-G19
in the D-loop [54,55]. Interestingly, the abundance of selected
50-tRF species (e.g. derived from tRNAsGln/Lys/Val/Arg) in HeLa cells
is comparable to the levels of abundant microRNAs such as
miR-21 or members of let-7 family [54]. Similarly, the abundance
of selected 50-tRFs (e.g. derived from tRNAsGlu/Ser/Leu/Gln) in prostate
cancer cell lines is greater than more than 90% of individual
microRNAs in these cells [55]. Dicer, an endoribonuclease involved
in the biogenesis of mature microRNA from microRNA precursors
[1], is responsible for processing of 50-tRFs from tRNA because siR-
NA-mediated silencing of Dicer signiﬁcantly decreases the abun-
dance of 50-tRFs [54]. However, it is also possible that 50-tRFs are
processed from larger tRNA intermediates, e.g. 50-tRNA halves,
and also in Dicer-independent manner [56]. 50-tRFs are cytoplas-
mic and also associate, although poorly, with Argounaute (Ago
1–4) proteins central to RISC (RNA-induced silencing complex)
functions [57]. Whether 50-tRFs play a direct role in RNAi (RNA
interference) is unknown but recently their role in translation inhi-
bition was proposed [58]. Sobala and Hutvagner reported that
selected 50-tRFs (3 out of 4 tested) inhibit translation of mRNA
reporters in vitro [58]. The molecular details of this inhibition
remain to be determined but they are proposed to affect transla-
tion elongation [58], which is different from the inhibition of trans-
lation initiation caused by 50-tiRNAs [30,32]. Interestingly, the
universally conserved G18–G19 dinucleotide at the 30-end of 50-
tRF is absolutely required for translation inhibition. The same
mutation in 50-tiRNAAla also affects 50-tiRNA-mediated repression
of translation approximately twofold [32]. An interesting parallel
is coming from studies in archaea: a stress-induced 26-nt 50-tRF
derived from tRNAVal inhibits translation by direct binding to the
30S small ribosomal subunit where it inhibits the peptidyl trans-
ferase activity of the ribosome [59]. Thus inhibition of translation
by 50-tRNA fragments appears to be an evolutionarily conserved
phenomenon.
The 30CCA-tRFs are tRNA fragments characterized by the
presence of a universal CCA trinucleotide at their 30-ends and are
produced from mature tRNAs by cleavage in the T-loop
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of 30CCA-tRFs is comparable to that of 50-tRFs and microRNAs. The
biogenesis of 30CCA-tRFs is proposed to be both Dicer-dependent
[60–63] and Dicer-independent (for example by ANG-mediated
cleavage in the T arm) [56]. Selected 30CCA-tRFs are found in
association with Argonautes and possess RNAi activities [61,62].
Pre-tRNAs can also be processed to produce fragments contain-
ing 50-leader, 30-trailer or intron-derived sequences (Fig. 1A). The
best-studied pre-tRNA-derived fragments belong to so-called
30U-tRFs (19–25 nt) that include the 30-trailer from pre-tRNA fol-
lowed by a 2–6 nt oligouridine stretch produced by terminating
RNA polymerase III [55,61,64]. Although biogenesis of 30U-tRFs is
natural and depends on the RNase Z-dependent cleavage of pre-
tRNA [55], one study proposed Dicer-dependent processing [60].
Surprisingly, 30U-tRFs are relatively stable molecules that are con-
centrated in the cytoplasm [55,64]. They are also present in human
embryonic stem cells and embryoid bodies [65]. Moreover, the bio-
genesis of 30U-tRFs is proposed to occur in the cytoplasm from pre-
tRNA by a cytoplasmic RNase Z homologue ELAC2 and might be
regulated by cell proliferation [55]. It is not clear how pre-tRNAs
are exported from the nucleus to the cytoplasm to produce 30U-
tRFs. In the cytoplasm, 30U-tRFs bind to Argonautes (preferentially
Ago3 and Ago4) and compete with cellular microRNAs and siRNAs
for incorporation into RISC complexes [61].
Mammalian intron-containing pre-tRNAs also produce a dis-
tinct subset of relatively stable tRFs [29,66,67] (Fig. 1A). Some of
these tRFs are splicing products of pre-tRNAs that lack leader and
trailer sequences. Although these fragments resemble tRNA halves,
they are concentrated in the nucleus rather than the cytoplasm.
Much larger tRFs containing 50-leader sequences followed by the
entire 50-exon of pre-tRNA (50-leader-exon-tRF, e.g. produced from
pre-tRNATyr/Arg) are predominantly nuclear and induced by oxida-
tive stress in an ANG-independent manner [29]. In some patholog-
ical conditions (discussed below), accumulation of relatively
abundant linear introns derived from pre-tRNA is also observed
[66]. Additional tRFs (e.g. derived from pre-tRNAIle/Tyr) containing
50-trailer sequences followed by a partial exon (50-leader-
partial-tRF) or 30-exon followed by 30-trailer sequences (30-partial-
exon-trailer) have been reported [66]. However these fragments
are less abundant than intron-containing and 50-leader-exon-tRFs,
and their functions are unknown.3. Possible roles of tRNA fragments in human disease
The production of tRNA-derived ncRNAs has been observed in a
number of human diseases. In some cases, these tRNA fragments
may serve as useful biomarkers. It remains to be determined
whether these tRNA fragments contribute to disease pathogenesis.
Below, we discuss examples in which the production of tRNA frag-
ments has been linked to cancer, infection, neurodegeneration and
other pathological conditions.3.1. tRNA fragments and pathological stress injuries
Cellular damage is central to disease pathogenesis. Stress
imparted by hypoxia, nutrient deprivation, oxidative conditions
and metabolic imbalance can damage cells and promote disease.
We and others observed that these stresses stimulate production
of tiRNAs [31,33]. In a recent study using animal models of tissue
damage (e.g., toxic injury, irradiation and ischemic reperfusion)
tiRNAs were found to serve as in vivo biomarkers whose produc-
tion correlated with the degree of tissue damage [68]. Combining
in vitro and in vivo studies Mishima et al. showed that oxidative
stress induces a change in tRNA conformation that promotes
ANG-mediated production of tiRNAs. This stress-inducedconformational change allows 1-methyladenosine nucleoside
(m1A), a modiﬁcation important for stabilizing the L-shaped struc-
ture of tRNA, to be recognized by an m1A-speciﬁc (Anti-m1a) anti-
body. This antibody recognizes 30-tiRNAs (containing m1A) as well
as free m1A nucleosides. This antibody was used to show that renal
ischemia/reperfusion (I/R) injury and cisplatin-mediated nephro-
toxicity (which both induce tissue damage via oxidative stress)
generate tiRNAs in damaged kidneys [68]. Similar results were
obtained using m1A-based immunohistochemistry to directly
visualize damaged areas of kidneys, brain and liver. Importantly,
the production of tiRNAs was found to be ANG dependent. Interest-
ingly, the conformational change in tRNA caused by various
injuries precedes DNA damage and apoptosis in vivo, which makes
detection of tRNA changes useful as an early stress biomarker. Con-
sequently, an m1A-based ELISA that detects tRNA derivatives
(unfolded tRNA, tiRNAs, smaller tRFs and free m1A) was used to
quantify circulating tRNA derivatives in both humans and animals
under different pathological settings (e.g., I/R, c-irradiation, sur-
gery, chronic kidney disease). The levels of circulating tRNA deriv-
atives were much higher under these conditions than in healthy
patients or control animals suggesting that levels of tRNA deriva-
tives can be used as early biomarkers of oxidative stress and tissue
damage [68].
Mishima et al. further demonstrated that tRNA-derived frag-
ments avoid degradation in the blood because they are associated
with circulating exosomes [68], membranous extracellular vesicles
packed with proteins and nucleic acids [69]. Dhabbi et al. similarly
quantiﬁed tRNA fragments in mouse and human serum [70]. These
30–33 nt fragments were found to be derived exclusively from the
50-ends of mature tRNAs. These fragments are not included in exo-
somes but are parts of 100–300 kDa protein–RNA complexes.
Interestingly, the source of these circulating 50-tiRNAs is mainly
hematopoietic and lymphoid tissues, and such physiological
changes as aging and calorie restriction modulate the appearance
of 50-tiRNAs from speciﬁc tRNA isoacceptors. Further studies are
required to decipher a casual relationship between circulating
50-tiRNAs and speciﬁc physiological/pathophysiological conditions.
3.2. tRNA fragments and cancer
It has been observed that cancer patients and tumor-bearing
animals excrete elevated levels of modiﬁed purines and pyrimi-
dines, and these modiﬁed nucleosides can originate only from
tRNAs [71–73]. Moreover, compared to unmodiﬁed RNA, such as
mRNAs or microRNAs, the high content of modiﬁed nucleotides
in tRNA confers ribonuclease resistance making it possible to
detect tRNA fragments even after excretion from cells [74]. It
was also shown that tumor tissues have a high rate of tRNA
turnover [71], and tRNA fragments can be detected in the serum
and urine of cancer patients [72,73]. Moreover the levels of tRNA
breakdown products correlate with the clinical stage of some
cancers.
The levels of tRNAs vary widely among normal (non-diseased)
human tissues (the level of variation is as much as tenfold) [75].
As cancer cells demand elevated levels of protein synthesis for
their increased proliferation and growth, this also requires a coor-
dinated adjustment of translation machinery components. Cancer
cells have higher levels of ribosomal RNAs, tRNAs and ribosomes
than non-cancerous cells. Genome-wide analysis of tRNA levels
in breast cancer cells versus normal breast tissues revealed that
tRNA levels (both nuclear-encoded and mitochondrial) are signiﬁ-
cantly increased in transformed cells [76]. This increase is selective
with over-expression of certain tRNA isoacceptors. Similarly, the
levels of tRNAs in multiple myeloma cells are signiﬁcantly elevated
compared to normal bone marrow cells [77]. Moreover, overex-
pression of initiator tRNA alone leads to global reprograming of
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of epithelial cells [78].
Whether the increase in tRNA levels results in an increase in
tRNA fragments in cancer cells is unknown. ANG is over-expressed
in almost all types of cancer (reviewed in [34,79,80]). It is an angio-
genic ribonuclease that promotes cancer cell proliferation and
induces tumor angiogenesis by stimulation of rRNA transcription
in endothelial and cancer cells [81]. The ribonuclease activity of
ANG is critical for its ability to promote angiogenesis [82], and
inhibition of the RNase activity by small molecule inhibitors signif-
icantly inhibits tumor formation in mouse xenograft tumor models
[83]. As ANG produces tiRNAs that re-program translation and pro-
mote the assembly of SGs that help cells to survive under adverse
conditions, it is possible that ANG-induced tiRNAs directly contrib-
ute to ANG-mediated angiogenesis and cancer cell proliferation.
Similarly, tiRNAs can help cancer cells to prevent apoptosis by
binding to Cyt c [51].
One of the 30U-tRFs (namely tRF-1001), derived from pre-
tRNASer, is highly expressed in different cancer cell lines, and is
required for proliferation of prostate cancer cells [55]. This frag-
ment is produced by cleavage of cytoplasmic pre-tRNA by ELAC2,
a prostate cancer susceptibility gene [84]. The levels of tRF-1001
in cancer cells are directly related to levels of cellular proliferation.
Knocking down this tRF causes a dramatic loss of cell viability and
inhibition of cell proliferation with speciﬁc accumulation of cells in
G2 phase and inhibition of DNA synthesis [55]. The molecular
mechanism by which tRF-1001 affects cell physiology is not
known. In addition, analysis of the small RNA transcriptome in
prostate cancer revealed enrichment of tRFs in both non-
metastatic and metastatic lymph node prostate cancer samples.
There may be a differential processing of tRNA in prostate cancer
because tRFs in non-metastatic samples were 18-nt long whereas
tRFs in metastatic tissues were 27 nt long [85].
Two reports showed the existence of tRFs in human B-cell lym-
phomas. Li et al. observed accumulation of both 50-tRFs (predomi-
nantly 14–15 nt) and 30CCA-tRFs (predominantly 17–18 nt, but
also shorter abundant species were observed) precisely matching
50- and 30-ends of mature tRNAs in the human primary-effusion
lymphoma cell line BCP1 [56]. At least two 30CCA-tRFs (derived
from His(GTG) and Leu(CAG) tRNAs) produced in a Dicer-indepen-
dent manner associate with Ago2 and direct Ago2-mediated cleav-
age of an mRNA reporter. Intriguingly, various 30CCA-tRFs are
complementary to the replication sites of human endogenous ret-
roviruses (HERV), which exist in the form of long terminal repeats
and comprise about 7% of the human genome [86]. Since retroviral
elements and retroviruses (such as HIV) use the binding of tRNAs
to retroviral primer binding sites (PBS) to initiate retroviral gen-
ome replication [87], it is possible that 30CCA-tRFs can direct
Ago2-mediated cleavage of retroviral RNAs and act as inhibitors
of HERV replication. In fact, small ncRNA cloned from T cells
infected with HIV-1 included an abundant 30-CCA-tRF correspond-
ing to an 18-nt fragment derived from tRNALys [63]. This tRF is
complimentary to the PBS of HIV-1, is enriched only in infected T
cells, and its levels correlate with HIV-1 expression.
Interestingly, another study describes a 22-nt 3’CCA-tRF (which
they called CU1276, derived from tRNAGly) in mature B cells that
has the functional characteristics of a microRNA [62]. CU1276 is
produced in a Dicer-dependent manner, associates with all four
human Argonautes (Ago 1–4) and functions as a miRNA. Moreover,
in B cell lymphomas, the expression of CU1276 is down-regulated
and its loss causes derepression of CU1276 endogenous targets
including RPA1, a protein involved in DNA replication and repair.
Further analysis suggests that CU1276 regulates cell proliferation
and DNA damage in an RPA1-dependent manner in lymphoma cell
lines. Decreased CU1276 expression in lymphomas may confer aselective growth advantage to malignant cells via increased RPA1
expression [62].
3.3. tRNA fragments and neurodegenerative diseases
Although tRNAmetabolism is absolutely essential for all human
cells, a number of neurological disorders are caused by defects in
tRNA metabolism and tRNA processing enzymes. In 2006, ANG
mutants possessing reduced ribonuclease (RNase) activity were
implicated in the pathogenesis of Amyotrophic Lateral Sclerosis
(ALS), a fatal neurodegenerative disease [88]. In 2012, a subset of
ALS-associated ANGmutants was also found in Parkinson’s Disease
(PD) patients [89]. Recombinant ANG is neuroprotective for cul-
tured motor neurons [90,91] and administration of ANG to
SOD1(G93A) mice, a standard laboratory model for ALS, signiﬁ-
cantly promotes both life-span and motor function [90]. As most
ALS/PD-associated mutations are RNase loss-of-function mutations
[92] and ANG-mediated neuroprotection is RNase-dependent, we
speculate that they affect production of tiRNAs required for cell
survival. Mechanistically, formation of tiRNAs may contribute to
motor neuron survival via its ability to inhibit apoptosis [51] or
promotion of SGs [30,32]. We are currently examining these
possibilities.
Recent work from Blanco et al. further strengthens the link
between ANG-induced tiRNAs, cellular stress and neurodevelop-
mental disorders [93]. Several mutations in the cytosine-5 RNA
methyltransferase NSun2 have been identiﬁed to cause a syn-
dromic form of intellectual disability (ID) and a Dubowitz-like syn-
drome in humans [94–96]. Human NSun2 methylates cytosine
residues in the anticodon loop (position C34) and at the intersec-
tion of the variable loop and the T arm of tRNA (positions 48/49/
50). The tRNA targets of NSun2 are limited to a subset of tRNA iso-
types (Asp, Glu, Gly, His, Lys and Val). In the absence of NSun2,
these tRNAs are non-methylated and prone to accumulate as 50-
tRNA fragments as a result of stress-induced ANG-mediated cleav-
age. Like classical 50-tiRNAs, these fragments repress translation,
and trigger a stress response and cell death in cortical, hippocam-
pal and striatal neurons. As a consequence, NSun2 knockout mouse
brains exhibit reduced neuronal size and impaired formation of
synapses. Ultimately, these mechanisms may explain the general
growth retardation and impaired intellectual development in
patients with mutations of NSun2 gene [93].
tRNA fragments derived from intron-containing tRNAs are also
strongly implicated in neurodegeneration [29,66,67]. Mutations in
the CLP1 gene (R140A) encoding an RNA kinase involved in tRNA
splicing, are found in patients with pontocerebellar hypoplasia
(PCH), a heterogeneous group of inherited neurodegenerative dis-
orders characterized by impaired development of various parts of
the brain. Animal models of CLP1 deﬁciency (in both mice and zeb-
raﬁsh) phenocopy developmental and neuromuscular defects
observed in PCH patients [29,66,67]. On the cellular level, the
R140A mutation leads to the depletion of mature tRNAs, accumu-
lation of unspliced pre-tRNAs in patient-derived neurons [67] and
accumulation of linear introns [66]. Transfection of 50-unphosphor-
ylated tRF corresponding to the 30-exon of pre-tRNATyr (the natural
substrate of CLP1) into patient cells results in reduced neuron
survival under oxidative stress compared to the transfection of
the 50-exon, which had no effect on viability [67]. The CLP1
kinase-dead mice accumulate 50-leader-exon-tRFs that sensitize
cells to oxidative stress and promote cell death in a p53-dependent
fashion [29]. While the exact mechanistic details on the interplay
between CLP1 activity, tRNA splicing and functions of pre-tRNA-
derived tRFs are yet to be uncovered, these studies provide a basis
for further investigations linking aberrant tRNA metabolism and
development of neurodegeneration.
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The human genome encodes hundreds of tRNA genes and
pseudogenes. A great number of tRNA genes possess the same anti-
codon but different sequences in the tRNA body. The beneﬁt of
having a collection of tRNA isodecoders in translation is unclear.
Such diversity in the nucleotide composition within the group of
isodecoders may have important consequences for tRNA
expression and/or allow the regulation of tRNA stability/pattern
of nucleotide modiﬁcations in tissue-speciﬁc and developmental
stage-speciﬁc manners. We propose here that tRNA diversity may
also provide substrates for the production of diverse classes of
small ncRNAs that have important effects on cell physiology.
The list of possible functions of tRNA-derived fragments is
growing. The recent discovery that the abundance of 50-tRNA
halves found in sperm and oocytes rapidly decreases upon fertil-
ization suggests that this class of molecules can be physiologically
regulated [97]. Similarly, 50-tRNA halves and 50-tRFs are found in
exosomes within semen [98]. The biogenesis and functions of these
sperm-born tRNA fragments is an open question. Additionally,
tRNAs and tRNA fragments were reported as novel sources of piR-
NAs (PIWI-interacting RNAs [1]) in both mouse gametes and
zygotes [99] as well as in human somatic cells [100]. The functions
of these tRNA-derived piRNAs are not known but may be con-
nected to epigenetic inheritance, silencing of retrotransposons
and other genetic elements or post-transcriptional regulation of
mRNAs. Finally, tRNA fragments are also induced by viral infec-
tions such as by Respiratory Syncytial Virus (RSV) [101]. RSV acti-
vates ANG to produce tiRNAs, and selected 50-tiRNAs (such as
derived from tRNAGlu) suppress expression of target mRNAs. Sig-
niﬁcantly, induction of tRNA fragments is required for replication
of RSV [101], although the exact molecular mechanisms of their
involvement in RSV infection remain unknown. Whether similar
mechanisms operate during infection by other viruses or patho-
genic microorganisms remains to be determined.
Studies on tRNA-derived fragments are still at a very early
stage. It is likely that additional functions for tRNA fragments will
be uncovered in the near future. Improved understanding of the
functions of tRNA-derived fragments will provide valuable insights
into human physiology and pathophysiology.References
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